Survival Varies by Race, Ethnicity for Nonmetastatic Castration-Resistant Prostate Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, Oct. 16, 2023 -- Differences in outcomes by race and ethnicity exist for men with nonmetastatic castration-resistant prostate cancer (nmCRPC); however, equal access to care appears to lessen these disparities, according to a study published online Oct. 11 in JAMA Network Open.
Kelli M. Rasmussen, from the University of Utah in Salt Lake City, and colleagues examined clinical outcomes by race and ethnicity in patients with nmCRPC within the U.S. Veterans Health Administration (2006 to 2021). The analysis included 12,992 veterans followed for a mean of 4.3 years. Time from the landmark period to death or metastasis was the primary outcome, while overall survival was the secondary outcome.
The researchers found that median time elapsed from nmCRPC to metastasis or death was 5.96 years for Black patients, 5.62 years for Hispanic patients, 4.11 years for White patients, and 3.59 years for other patients. Median unadjusted overall survival was 6.26 years overall but was from 8.36 years for Black patients, 8.56 years for Hispanic patients, 5.48 years for White patients, and 4.48 years for other patients.
"The findings of this study suggest that the availability of equal-access care may reduce and even reverse racial and ethnic disparities in patients," the authors write. "In addition, Black and Hispanic men may have considerably improved outcomes when treated in an equal-access setting."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Planetary Health Diet Index Linked to Lower Total, Cause-Specific Mortality
MONDAY, June 10, 2024 -- A higher Planetary Health Diet Index (PHDI) is associated with a lower risk for total and cause-specific mortality, according to a study published online...
Prevalence of Iron Deficiency Varies With Different Definitions
MONDAY, June 10, 2024 -- The prevalence of iron deficiency varies significantly with three different definitions, according to a study published online June 7 in JAMA Network...
AI Blood-Based Lung Cancer Screening Test Developed for Fragmentome
MONDAY, June 10, 2024 -- A novel blood-based lung cancer screening test has been developed and validated using genome-wide sequencing to analyze cell-free DNA (cfDNA)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.